Vaxis Therapeutics Corp.

Vaxis Therapeutics enters a market made popular by {Viagra}: it is developing both oral and local therapies for male and female sexual dysfunction.

Defined as the inability (over the course of three months) to achieve an erection sufficient to perform sexual intercourse, less than 5% of the male population suffering from erectile dysfunction seeks help. Despite this, according to a recent Cowen & Co. report, the worldwide market for erectile dysfunction therapies is currently $500 million annually and could reach as much as $8 billion by 2002. A peripheral vascular disease therapeutic company, Vaxis Therapeutics Corp. , will focus its first products in this specific market niche in an attempt to penetrate this potentially huge opportunity. Through the development of both oral and local therapies, Vaxis hopes to become a player in the increasingly competitive field of treating male sexual dysfunction disorders.

Existing erectile dysfunction therapies range from oral therapies such as Pfizer Inc. 's Viagra,to vasodilators delivered by needle, with...

More from Archive

More from Scrip

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.